Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) shares traded up 2.3% on Friday . The company traded as high as $14.85 and last traded at $14.83, with a volume of 253,073 shares trading hands. The stock had previously closed at $14.49.

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $16.00 target price on shares of Lexicon Pharmaceuticals in a research report on Thursday, May 5th. Wedbush reaffirmed an “outperform” rating and issued a $28.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, May 6th. Cowen and Company reaffirmed a “market perform” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, May 3rd. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $18.50.

The stock has a 50 day moving average price of $14.26 and a 200-day moving average price of $12.28. The company’s market capitalization is $1.56 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.04. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $11.11 million. The firm’s revenue for the quarter was up 594.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.04) EPS. On average, equities analysts forecast that Lexicon Pharmaceuticals Inc. will post ($1.55) earnings per share for the current year.

In related news, VP James F. Tessmer sold 6,000 shares of the business’s stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $78,000.00. Following the transaction, the vice president now owns 21,946 shares in the company, valued at approximately $285,298. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of hedge funds have made changes to their positions in the stock. New York State Common Retirement Fund raised its stake in shares of Lexicon Pharmaceuticals by 240.2% in the fourth quarter. New York State Common Retirement Fund now owns 177,168 shares of the biopharmaceutical company’s stock worth $2,358,000 after buying an additional 125,083 shares during the period. Nationwide Fund Advisors raised its stake in shares of Lexicon Pharmaceuticals by 124.1% in the fourth quarter. Nationwide Fund Advisors now owns 139,876 shares of the biopharmaceutical company’s stock worth $1,862,000 after buying an additional 77,446 shares during the period. ProShare Advisors LLC raised its stake in shares of Lexicon Pharmaceuticals by 7.7% in the fourth quarter. ProShare Advisors LLC now owns 89,382 shares of the biopharmaceutical company’s stock worth $1,190,000 after buying an additional 6,390 shares during the period. Finally, California State Teachers Retirement System raised its stake in shares of Lexicon Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 76,947 shares of the biopharmaceutical company’s stock worth $1,024,000 after buying an additional 1,372 shares during the period.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.